BRIDGING SCIENCE AND PATIENTS
Key updates as of June 4th, as presented during the 2020 Mirae Asset Daewoo Securities Corporate Day event
We have updated our official IR presentation as of June 4th, 2020, as presented during the online investor event hosted by Mirae Asset Daewoo Securities. The updated IR presentation has been released on our website and the corporate disclosure bulletin operated by the Korea Exchange.
We have completed the patient enrollment process for the first dose cohort of our BBT-401 (ulcerative colitis treatment) Phase II study (total of 16 patient participants). While we are experiencing some minor delays due to the on-going COVID-19 pandemic, we seek to complete the first cohort study as soon as possible and progress to the second dose cohort thereafter.
We are also planning to expand the indication of our Pellino-1 inhibitor to include psoriasis. In addition to formulation development and efficacy studies, we seek to verify and prove that our Pellino-1 inhibitor can be developed as an external skin treatment for psoriasis.
During our March 2020 IR event we announced that we were expecting the Phase II study of our BBT-877 treatment (Idiopathic pulmonary fibrosis treatment) to begin in the 3rd quarter of 2020 and due to the fact that we are nearing that juncture, we felt obligated to provide the following update.
We have completed the Phase I study for BBT-877 and are awaiting Boehringer Ingelheim’s decision regarding the initiation of the Phase II study. Additionally, given that our partner company Boehringer Ingelheim acquired the global exclusive rights for BBT-877, Boehringer Ingelheim will determine all factors relating to the development timeline. In conclusion, due to various unforeseeable factors, we believe that it will be difficult to begin the Phase II study in the 3rd quarter. In addition, we would like to clarify that contract cancellation rumors are false.
We will continue to provide timely notifications to our shareholders on further development timeline updates that arise through communications between Bridge Biotherapeutics and Boehringer Ingelheim.
We would like to assure you that we are working diligently to develop novel treatments that will address the unmet medical needs of patients. Furthermore, and despite the COVID-19 pandemic, we will continue to strive to provide transparent and timely updates to our shareholders.
We would like to take this opportunity to thank our shareholders in kind for your unwavering support in our company.